Inventiva (NASDAQ:IVA – Get Free Report) and Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.
Institutional and Insider Ownership
19.1% of Inventiva shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Inventiva and Kiora Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inventiva | $5.07 million | 191.73 | -$400.67 million | N/A | N/A |
| Kiora Pharmaceuticals | $16.02 million | 0.73 | -$10.84 million | ($2.51) | -1.06 |
Kiora Pharmaceuticals has higher revenue and earnings than Inventiva.
Volatility and Risk
Inventiva has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.38, meaning that its stock price is 138% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings for Inventiva and Kiora Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inventiva | 1 | 0 | 7 | 3 | 3.09 |
| Kiora Pharmaceuticals | 1 | 0 | 1 | 0 | 2.00 |
Inventiva currently has a consensus price target of $16.56, suggesting a potential upside of 253.75%. Kiora Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 275.94%. Given Kiora Pharmaceuticals’ higher possible upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Inventiva.
Profitability
This table compares Inventiva and Kiora Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inventiva | N/A | N/A | N/A |
| Kiora Pharmaceuticals | N/A | -63.38% | -44.33% |
Summary
Inventiva beats Kiora Pharmaceuticals on 8 of the 12 factors compared between the two stocks.
About Inventiva
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.
